Atezolizumab, durvalumab and avelumab are anti-PD-L1 IgG1 mAbs that target PD-L1, the main ligand of PD-1, along with PD-L2, which is constitutively expressed on APCs within the TME as well as a wide range of tumours, such as lung, breast, and melanoma, thereby disinhibiting the migration and activation of T cells to seek and destroy PD-L1-expressing cancer cells [39,40]. Here, PDCD1LG2 is linked to neoplasm.